Jonathan G. Drachman - Aug 24, 2021 Form 4 Insider Report for Neoleukin Therapeutics, Inc. (NLTX)

Role
President and CEO, Director
Signature
/s/ Robert Ho, as Attorney-in-Fact for Jonathan Drachman
Stock symbol
NLTX
Transactions as of
Aug 24, 2021
Transactions value $
$933,550
Form type
4
Date filed
8/26/2021, 07:08 PM
Previous filing
Aug 5, 2021
Next filing
Nov 10, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction NLTX Common Stock Purchase $611K +100K +4.45% $6.11 2.35M Aug 24, 2021 Direct F1
transaction NLTX Common Stock Purchase $161K +25K $6.45* 25K Aug 25, 2021 See footnote F2, F3
transaction NLTX Common Stock Purchase $161K +25K $6.45* 25K Aug 25, 2021 See footnote F2, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents the weighted average purchase price. The lowest price at which shares were purchased was $6.1099 and the highest price at which shares were purchased was $6.1482. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares purchased at each separate price within the ranges set forth in footnotes (1) and (2) to this Form 4.
F2 Represents the weighted average purchase price. The lowest price at which shares were purchased was $6.09 and the highest price at which shares were purchased was $6.60.
F3 These securities are held by a spousal limited access trust of which the Reporting Person is the primary beneficiary.
F4 These securities are held by a spousal limited access trust of which the Reporting Person's spouse is the primary beneficiary.